Results 211 to 220 of about 72,405 (280)
Medical Optimization of the Patient with Perianal Fistulizing Crohn's Disease Prior to Definitive Closure. [PDF]
Zoughlami A, Jairath V, Singh S.
europepmc +1 more source
Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics. [PDF]
Bartel C +15 more
europepmc +1 more source
In this meta‐analysis of eight studies (508 children with inflammatory bowel disease), switching from originator to biosimilar infliximab preserved clinical remission, drug exposure, and immunogenicity, with high treatment persistence and no signal of efficacy or safety loss. Biosimilar switching appears a safe, effective option in pediatric IBD.
Douglas Amaral da Silva Menegazzo Miotto +4 more
wiley +1 more source
Severe ectopic hidradenitis suppurativa refractory to adalimumab. [PDF]
Ajmani A +4 more
europepmc +1 more source
ABSTRACT Background Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and ...
John P. Thomas +14 more
wiley +1 more source
An international modified Delphi study identified stakeholder consensus on population, interventions, comparators and outcomes to inform development of a future multi‐arm, multi‐stage adaptive platform trial for Crohn's disease. ABSTRACT Background and Aims The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in ...
Shellie J. Radford +15 more
wiley +1 more source
Recurrent Cryptogenic Ulcerative Tracheobronchitis 6 Years After Lung Transplantation: Case Report. [PDF]
Brookes S +8 more
europepmc +1 more source
This national, multisite, nurse‐led evaluation highlights practice patterns across UK IBD centres, revealing reliance on reactive flare‐driven treatment modification. Balancing this with structured proactive surveillance and therapeutic drug monitoring aligns with treat‐to‐target principles and supports safer advanced therapy care across diverse ...
Vida Cairnes +18 more
wiley +1 more source

